Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents

CONCLUSIONS: The introduction of cabazitaxel as a third-line agent could markedly improve the prognostic outcomes of mCRPC patients.PMID:34255227 | DOI:10.1007/s10147-021-01956-2

Source: Clinical Prostate Cancer - July 13, 2021 Category: Cancer & Oncology Authors: Hideaki Miyake Ryo Sato Kyohei Watanabe Yuto Matsushita Hiromitsu Watanabe Daisuke Motoyama Toshiki Ito Takayuki Sugiyama Atsushi Otsuka Source Type: research